Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

ClinicalTrials.gov ID: NCT05786924

Public ClinicalTrials.gov record NCT05786924. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Study identification

NCT ID: NCT05786924
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Institut de Recherches Internationales Servier; Other
Enrollment: 554 participants

Conditions and interventions

Conditions

Interventions

Cetuximab Drug
FOLFIRI Drug
FOLFOX6/FOLFOX7 Drug
Gemcitabine Drug
Nab-paclitaxel Drug
Panitumumab Drug
S241656 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 17, 2023
Primary completion: May 31, 2028
Completion: May 31, 2028
Last update posted: Apr 20, 2026

2023 – 2028

United States locations

U.S. sites: 10
U.S. states: 10
U.S. cities: 10

Facility	City	State	ZIP	Site status
Banner Health- MD Anderson Cancer Center	Gilbert	Arizona	85234	Recruiting
University of Colorado - Aurora Cancer Center	Aurora	Colorado	80045	Not yet recruiting
Georgetown University Lombardi Cancer Center	Washington D.C.	District of Columbia	20007	Not yet recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
South Texas Accelerated Research Therapeutics (START) Midwest	Grand Rapids	Michigan	49546	Recruiting
Masonic Cancer Center University of Minnesota	Minneapolis	Minnesota	55455	Recruiting
Washington University	St Louis	Missouri	63130	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
NEXT Virginia	Fairfax	Virginia	22031	Recruiting
Fred Hutchinson Cancer Research Center	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05786924, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 20, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05786924 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →